Tumor Dendritic Cells (DCs) Derived from Precursors of Conventional DCs Are Dispensable for Intratumor CTL Responses.

ABSTRACT: The success of adoptive CTL therapy for cancer depends on interactions between tumor-infiltrating CTLs and cancer cells as well as other cells and molecules in the tumor microenvironment. Tumor dendritic cells (DCs) comprise several subsets: CD103⁺CD11b^- DC1 and CD11b⁺CD64^- DC2, which originate from circulating precursors of conventional DCs, and CD11b⁺CD64⁺ DC3, which arise from monocytes. It remains controversial which of these subset(s) promotes intratumor CTL proliferation, expansion, and function. To address this issue, we used the Zbtb46-DTR-transgenic mouse model to selectively deplete DC1 and DC2 from tumors and lymphoid tissues. Wild-type and Zbtb46-DTR bone marrow chimeras were inoculated with B16 melanoma cells th

SUBMITTER: Diao J 

PROVIDER: S-EPMC6077850 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature